1. In Vivo

Financing Quarterly Statistics, Q3 2022

A Look At Financing Activity Across The Biopharma, Medical Device And In Vitro Diagnostics Industries, July-September 2022

 
• By Deanna Kamienski and Maureen Riordan

During Q3, biopharmas brought in an aggregate $18.1bn in financing and device company fundraising totaled $5.1bn; while in vitro diagnostic firms and research tools players raised $771m.

Qstats Image 1
• Source: Alamy

Biopharma financings during the third quarter of 2022 totaled $18.1bn from 236 deals. The largest was a $1.39bn royalty sale by Theravance Biopharma to Royalty Pharma, which acquired an 85% royalty interest in Theravance Biopharma Inc.’s asthma/COPD drug Trelegy Ellipta (fluticasone furoate, umeclidinium, vilanterol) for $1.1bn in cash up front and up to $250m in additional payments contingent on the achievement of certain sales milestones anticipated to occur between 2023-2026.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deal-Making

More from In Vivo

Podcast: Ochre Bio’s Approach To Precision Medicine In Liver Treatment

 
• By David Wild

Ochre Bio co-founder and CSO Quin Wills spoke with In Vivo about the UK-based company's novel approach to finding RNA therapies for chronic liver disease.

Richard DiMarchi On The GLP-1 Revolution: An Overnight Success After 40 Years

 
• By Andrew Warmington

As GLP-1 agonists surge to blockbuster status transforming diabetes and obesity treatment, Richard DiMarchi, the pioneering scientist behind their development, recounts the inside story of the drug class in a fireside chat.

Rising Leaders 2025: João Ribas On Building At The Intersection Of Science And Business

 
• By Jo Shorthouse

João Ribas combines scientific expertise with venture capital at Novo Holdings, applying his dual background to develop biotech investments that connect academic research with commercial opportunity.